Migraine Management on the Move
ValuateHealth.com | EntreeHealth.com
MIGRAINE MANAGEMENT ON THE MOVE
Migraines are a leading cause of disability across the United States and affect approximately 39 million Americans. Despite this clinical significance, research and development for migraine disease has lagged behind.
Until now.
The patient and provider push for novel migraine treatment has propelled multiple manufacturers forward. Reyvow, an oral ditan therapy, was approved on October 11, 2019 to treat acute migraines. And through 2021, at least 4 novel migraine treatments are expected to enter the market.
Migraine treatment pipeline
1. ubrogepant
An oral CGRP Inhibitor slated to provide acute migraine relief within 2 hours of ingestion and lasts for up to 48 hours2. rimegepant
An oral CGRP Inhibitor intended to provide acute migraine relief as quickly as 1 hour and lasts for up to 48 hours. Rimegepant is also being tested as a preventative modality3. BHV-3500
An intranasal CGRP Inhibitor spray that may relieve acute migraines within 2 hours for up to 48 hours4. eptinezumab
A biologic prophalytactic CGRP Inhibitor delivered as a quarterly antibody infusion to reduce the number of migraine-days for acute and chronic sufferers
KEEP UP WITH THE PACE
Although each of these products has unique features that require unique review, product price will pay a critical role in determining value. Nonetheless, the chronic, disabling nature of migraine headaches cannot be overlooked. Value stories that reflect total cost of care will be imperative to showcase the impact of migraine-free days.
Payer understanding of migraine disease has lagged. Payers will likely employ high utilization management of these pipeline products. However, headache specialists across the country are energized by these new treatments and are ready to put up a fight for the clinical treatment that provides the most relief for desperate patients. We see a perfect opportunity for manufacturers to meet in the middle.
OUT OF THE GATE
Thoughtful product strategy targeted to diverse stakeholders is imperative to move migraine management in the right direction. Educational pre-launch payer communications will give payers a chance to level set on the progress migraine management has made. Kickstart these disease ed conversations with payers before you think you’re ready.
How can we help you find your way in to strategic migraine management?
